Skip to main content
Erschienen in: Medical Oncology 4/2011

01.12.2011 | Original paper

VARS2 V552V variant as prognostic marker in patients with early breast cancer

verfasst von: Yee Soo Chae, Soo Jung Lee, Joon Ho Moon, Byung Woog Kang, Jong Gwang Kim, Sang Kyun Sohn, Jin Hyang Jung, Ho Yong Park, Ji Young Park, Hye Jung Kim, Sang-Woo Lee

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

The present study analyzed the polymorphisms of DNA repair genes and their impact on the survival of 240 patients with early breast cancer. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen polymorphisms in 12 DNA repair genes were determined using the Sequenom Mass array system. Among the target polymorphisms, VARS2 rs2074511 and POLE rs5744857 were found to correlate with survival after curative surgery in a log-rank test. No difference was found in the clinical and tumor characteristics according to the genotypes of these two coding variants, except for a higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (P = 0.025). Meanwhile, a multivariate analysis showed that the GG genotype of VARS2 V552 V (rs2301717) was significantly associated with disease-free survival (DFS; HR = 0.298; P = 0.044) and marginally with distant DFS (DDFS; HR = 0.266; P = 0.077). In particular, the VARS2 rs2074511 polymorphism was only associated with survival in patients with triple negative (TN)-type breast cancer (P = 0.018 for DFS and 0.042 for DDFS, respectively). In conclusion, VARS2 V552V may be considered as a prognostic factor for survival in patients with early breast cancer.
Literatur
1.
Zurück zum Zitat Trojan J, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 2002;122(1):211–9.PubMedCrossRef Trojan J, et al. Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. 2002;122(1):211–9.PubMedCrossRef
2.
Zurück zum Zitat Hutter P, Couturier A, Rey-Berthod C. Two common forms of the human MLH1 gene may be associated with functional differences. J Med Genet. 2000;37(10):776–81.PubMedCrossRef Hutter P, Couturier A, Rey-Berthod C. Two common forms of the human MLH1 gene may be associated with functional differences. J Med Genet. 2000;37(10):776–81.PubMedCrossRef
3.
Zurück zum Zitat Shin A, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev. 2008;9(3):501–5.PubMed Shin A, et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev. 2008;9(3):501–5.PubMed
4.
Zurück zum Zitat Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513–30.PubMed Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513–30.PubMed
5.
Zurück zum Zitat Li J, et al. Genetic polymorphisms in the DNA repair enzyme ERCC2 and breast tumour risk in a Chinese population. J Int Med Res. 2008;36(3):479–88.PubMed Li J, et al. Genetic polymorphisms in the DNA repair enzyme ERCC2 and breast tumour risk in a Chinese population. J Int Med Res. 2008;36(3):479–88.PubMed
6.
Zurück zum Zitat Pooley KA, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3482–9.PubMedCrossRef Pooley KA, et al. Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3482–9.PubMedCrossRef
7.
Zurück zum Zitat Poplawski T, et al. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treat. 2005;94(3):199–204.PubMedCrossRef Poplawski T, et al. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treat. 2005;94(3):199–204.PubMedCrossRef
8.
Zurück zum Zitat Shu XO, et al. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1462–7.PubMed Shu XO, et al. A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1462–7.PubMed
9.
Zurück zum Zitat Yuan HY, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34(Web Server issue):W635–41.PubMedCrossRef Yuan HY, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34(Web Server issue):W635–41.PubMedCrossRef
10.
Zurück zum Zitat Rorbach J, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res. 2008;36(9):3065–74.PubMedCrossRef Rorbach J, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res. 2008;36(9):3065–74.PubMedCrossRef
11.
Zurück zum Zitat Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50–5.PubMedCrossRef Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50–5.PubMedCrossRef
12.
Zurück zum Zitat Vogel CL, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.PubMedCrossRef Vogel CL, et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):37–42.PubMedCrossRef
13.
Zurück zum Zitat Nangle LA, Motta CM, Schimmel P. Global effects of mistranslation from an editing defect in mammalian cells. Chem Biol. 2006;13(10):1091–100.PubMedCrossRef Nangle LA, Motta CM, Schimmel P. Global effects of mistranslation from an editing defect in mammalian cells. Chem Biol. 2006;13(10):1091–100.PubMedCrossRef
14.
Zurück zum Zitat Bacher JM, Schimmel P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc Natl Acad Sci USA. 2007;104(6):1907–12.PubMedCrossRef Bacher JM, Schimmel P. An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc Natl Acad Sci USA. 2007;104(6):1907–12.PubMedCrossRef
15.
Zurück zum Zitat Ropcke G, Moen CJ, Hart AA, Demant P. Effects of the MHC on hormonal induction of mammary tumors and function of hypophyseal isografts in the mouse. Immunogenetics. 1990;31(5–6):347–55.PubMedCrossRef Ropcke G, Moen CJ, Hart AA, Demant P. Effects of the MHC on hormonal induction of mammary tumors and function of hypophyseal isografts in the mouse. Immunogenetics. 1990;31(5–6):347–55.PubMedCrossRef
16.
Zurück zum Zitat Dux A, Demant P. MHC-controlled susceptibility to C3H-MTV-induced mouse mammary tumors is predominantly systemic rather than local. Int J Cancer. 1987;40(3):372–7.PubMedCrossRef Dux A, Demant P. MHC-controlled susceptibility to C3H-MTV-induced mouse mammary tumors is predominantly systemic rather than local. Int J Cancer. 1987;40(3):372–7.PubMedCrossRef
17.
Zurück zum Zitat van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics. 2001;53(8):656–61.PubMedCrossRef van Kooij M, de Groot K, van Vugt H, Aten J, Snoek M. Genotype versus phenotype: conflicting results in mapping a lung tumor susceptibility locus to the G7c recombination interval in the mouse MHC class III region. Immunogenetics. 2001;53(8):656–61.PubMedCrossRef
18.
Zurück zum Zitat Malkki M, Gooley T, Horowitz M, Petersdorf EW. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007;69(Suppl 1):46–9.PubMedCrossRef Malkki M, Gooley T, Horowitz M, Petersdorf EW. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007;69(Suppl 1):46–9.PubMedCrossRef
19.
Zurück zum Zitat Harney SM, et al. Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1761–7.CrossRef Harney SM, et al. Fine mapping of the MHC Class III region demonstrates association of AIF1 and rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1761–7.CrossRef
20.
Zurück zum Zitat Snoek M, Teuscher C, van Vugt H. Molecular analysis of the major MHC recombinational hot spot located within the G7c gene of the murine class III region that is involved in disease susceptibility. J Immunol. 1998;160(1):266–72.PubMed Snoek M, Teuscher C, van Vugt H. Molecular analysis of the major MHC recombinational hot spot located within the G7c gene of the murine class III region that is involved in disease susceptibility. J Immunol. 1998;160(1):266–72.PubMed
21.
Zurück zum Zitat Fijneman RJ, Oomen LC, Snoek M, Demant PA. A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex. Immunogenetics. 1995;41(2-3):106–9.PubMedCrossRef Fijneman RJ, Oomen LC, Snoek M, Demant PA. A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex. Immunogenetics. 1995;41(2-3):106–9.PubMedCrossRef
22.
Zurück zum Zitat Lanning D, Lafuse WP. The mouse p52 subunit of the transcription/DNA repair factor TFIIH is located in the class III region of the H2 complex: cloning and sequence polymorphism. Immunogenetics. 1999;49(6):498–504.PubMedCrossRef Lanning D, Lafuse WP. The mouse p52 subunit of the transcription/DNA repair factor TFIIH is located in the class III region of the H2 complex: cloning and sequence polymorphism. Immunogenetics. 1999;49(6):498–504.PubMedCrossRef
Metadaten
Titel
VARS2 V552V variant as prognostic marker in patients with early breast cancer
verfasst von
Yee Soo Chae
Soo Jung Lee
Joon Ho Moon
Byung Woog Kang
Jong Gwang Kim
Sang Kyun Sohn
Jin Hyang Jung
Ho Yong Park
Ji Young Park
Hye Jung Kim
Sang-Woo Lee
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9574-4

Weitere Artikel der Ausgabe 4/2011

Medical Oncology 4/2011 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.